Filing Overview
Registrant: I-MAB, a foreign private issuer headquartered in Shanghai, China. The provided filing identifies I-MAB, not Novabridge Biosciences.
Form and period: Form 6-K for the month of May 2022, filed May 5, 2022, under Commission File Number 001-39173. The filing references a press release as Exhibit 99.1, but the press release text was not provided.
Financial and Operating Metrics
The provided filing text does not include revenue, profit or loss, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Changes
The filing text does not provide information on changes versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
The filing text does not provide guidance, management commentary, risk disclosures, contingencies, or unusual items. Any substantive information may be contained in Exhibit 99.1, which is not included in the supplied content.
Investor Verification Items
- Confirm the intended company, because the request names Novabridge Biosciences while the filing identifies I-MAB.
- Obtain and review Exhibit 99.1, the referenced press release.
- Verify the filing’s underlying financial results, liquidity position, outlook, and any material developments from the complete submission.